Last week saw two developments by players large and small in a universal flu vaccine race that's heating up. Now, Israel-based BiondVax is following up with some news of its own: It's partnering with the National Institute of Allergy and Infectious Diseases to test its candidate in the U.S.
Shire and Sangamo Biosciences are going their separate ways after three-plus years of collaboration in gene editing, with each company hanging on to the programs best aligned to its goals.
The U.S. Food and Drug Administration and the Fogarty Institute for Innovation, one of the more prominent medical device incubators, have developed a new educational program designed to improve collaboration between medical device innovators and the FDA that's expected to make the device approval process more efficient.
Hong Kong's Medisun International and Belgium-based cell therapy company Celyad said the terms of a collaboration for Greater China registration and distribution of C-Cure have changed from a June 2014 deal that saw €25 million raised through the sale of shares to Medisun and a joint venture formed.
Amgen is buying into Novartis' early-stage BACE program for Alzheimer's, paying an unspecified upfront and milestones in exchange for a cut of the program, which looks to slash the production of a key toxic protein widely viewed as a prime suspect in the development of the memory-wasting ailment.
Sanofi is backing out of a collaboration with Ardelyx that could have paid out nearly $200 million, returning a handful of candidate treatments for high phosphates in patients with kidney disease.
Digital health startup DynoSense is teaming up with a Chinese health services company to bring its patient monitoring technology to China, expanding its global reach weeks after the company reeled in new funds to fuel stateside approval for its device.
Three months after Amgen washed its hands of the psoriasis drug brodalumab, its development partner AstraZeneca has found the exit door as well. The pharma giant auctioned off the Phase III-complete therapy to the wheeler dealers at Valeant in exchange for $100 million upfront, $170 million in prelaunch milestones and another $175 million in sales bonuses.
Sanofi is lending its weight to Google's ambitions in life sciences, joining the tech giant's recently unleashed healthcare division in hopes of developing new technologies to help manage diabetes.
Google is teaming up with French drugmaker Sanofi for a diabetes monitoring collaboration, furthering the tech giant's foray into medical devices and its commitment to developing innovative products for the disease.